Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...

An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformi ...

Experts have hailed a powerful new weapon in the fight against Type 2 diabetes – a simple daily pill that can help people shed pounds and bring their blood sugar levels under control. Orfroglipron, ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...

Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more ...

Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss ‌pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes ‌patients, ...

A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works about as well as injectable semaglutide for people with type 2 diabetes.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

A pill already on the market might help slow progression of type 1 diabetes Baricitinib taken daily preserved people’s insulin production and stabilized their blood sugar The pill is already approved ...

Breakthrough research shows diabetes medicine metformin may reduce age-related vision loss by 37%. Liverpool study offers hope for AMD treatment.